Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc, filed a Form 4 on November 3, 2026, disclosing option exercises and open-market sales of Class A Ordinary Shares on November 2, 2026, all conducted under a pre-established 10b5-1 trading plan.

Key Highlights

  • Four option tranches exercised: Ragosa exercised share options covering 9,636, 5,388, 12,123, and 9,636 Class A Ordinary Shares at exercise prices of $10.76, $11.10, $11.97, and $17.76, respectively, all on November 2, 2026.
  • Shares sold in four tranches: A total of 36,783 Class A Ordinary Shares were disposed of at weighted average prices of $91.40, $92.03, $93.13, and $94.01, in separate tranches of 14,027, 10,502, 12,034, and 220 shares.
  • Resulting ownership: Following all reported transactions, Ragosa directly held 20,854 Class A Ordinary Shares, according to the filing.
  • 10b5-1 plan: All transactions were effected pursuant to a Rule 10b5-1 plan executed by Ragosa on July 29, 2026.
  • Remaining derivative securities: After the exercises, Ragosa retained 4,380 share options at $10.76 (expiring March 31, 2033) and 8,760 share options at $17.76 (expiring August 31, 2033), with the $11.10 and $11.97 tranches fully exercised to zero.
  • Issuer and exchange: The issuer is Kiniksa Pharmaceuticals International, plc, trading on NASDAQ:KNSA.

Ragosa's November 2 Option Exercises and Share Sales Under 10b5-1 Plan

According to the Form 4 filed November 3, 2026, Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), exercised four tranches of share options on November 2, 2026. The exercises covered 9,636 shares at $10.76, 5,388 shares at $11.10, 12,123 shares at $11.97, and 9,636 shares at $17.76, each acquired at the respective exercise price. The filing notes that the exercise price of each derivative security was $0 for the purpose of Table II, reflecting the cost to exercise reported separately as the per-share option prices listed.

On the same date, Ragosa disposed of shares in four separate sales. The largest tranche involved 14,027 shares sold at a weighted average price of $91.40, with individual trade prices ranging between $90.695 and $91.675. A second tranche of 10,502 shares was sold at a weighted average of $92.03 (range: $91.695 to $92.60). A third tranche of 12,034 shares was sold at a weighted average of $93.13 (range: $92.735 to $93.725), and a final tranche of 220 shares was sold at a weighted average of $94.01 (range: $93.93 to $94.025). The filing states that upon request, the reporting person will provide full information to SEC staff on the number of shares sold at each price within each tranche.

All eight transactions - the four option exercises (transaction code M) and four open-market sales (transaction code S) - were conducted pursuant to a 10b5-1 plan that Ragosa executed on July 29, 2026, as disclosed in the filing's explanatory footnotes. After all reported activity, Ragosa's direct beneficial ownership stood at 20,854 Class A Ordinary Shares, with 4,380 and 8,760 share options remaining in two separate tranches.

What Was Disclosed

The filing reports that CFO Mark Ragosa exercised four share option grants totaling 36,783 shares and sold 36,783 Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc on November 2, 2026, all under a 10b5-1 plan established July 29, 2026, leaving him with 20,854 shares directly owned.